CoChat

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults

Open access
Faison, Shamia L., Fry, Nicholas, Adewole, Toyin, Odebo, Oyinkansola, Wang, Zhao, Maletic, Vladimir, Nasser, Azmi · 2021 · Journal of Clinical Psychopharmacology
Cited by 28

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: Viloxazine extended-release is a novel nonstimulant under investigation as a potential treatment for attention-deficit/hyperactivity disorder (ADHD). Given the potential for viloxazine extended-release to be co-administered with stimulant ADHD pharmacotherapies, this trial investigated the pharmacokinetics and safety of combination viloxazine extended-release + lisdexamfetamine dimesylate (lisdexamfetamine) versus viloxazine extended-release and lisdexamfetamine alone. Methods: In this single-center, cross-over, open-label trial, healthy, non-ADHD adults received single oral doses of 700 mg viloxazine extended-release alone, 50 mg lisdexamfetamine alone, and a combination of viloxazine extended-release (700 mg) + lisdexamfetamine (50 mg), with blood samples collected over 4 days postadministration. The active drug in viloxazine extended-release (viloxazine) and primary metabolite of lisdexamfetamine (d -amphetamine) were measured using chromatographic tandem mass spectrometry. Safety assessments included adverse events, vital signs, echocardiograms, and clinical laboratory evaluations. Results: Thirty-six adults were enrolled, and 34 completed the trial. The least squares geometric mean ratios are reported as [combination / single drug (90% confidence intervals)]. Viloxazine extended-release: C max = 95.96% (91.33–100.82), area under the concentration–time curve from 0 to the last measurable time (AUC 0-t) = 99.19% (96.53–101.91), and area under the concentration–time curve from 0 to infinity (AUC inf) = 99.23% (96.61–101.93). Lisdexamfetamine: C max = 112.78% (109.93–115.71), AUC 0-t = 109.64% (105.25–114.22), and AUC inf = 109.52% (105.19–114.03). All reported adverse events, except 1 (moderate vomiting), were mild in severity. Conclusions: Co-administration of viloxazine extended-release and lisdexamfetamine did not impact the pharmacokinetics of viloxazine or d -amphetamine relative to administration of either drug alone. After single dose administration, the combination appeared to be safe and well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000001361

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 28

Metadata

Authors
Faison, S. L., Fry, N., Adewole, T., Odebo, O., Wang, Z., Maletic, V., & Nasser, A.
Venue
Journal of Clinical Psychopharmacology
Published
2021-02-12
Volume
41
Issue
2
Pages
155-162
ISSN
  • 0271-0749 (ISSN-L)
  • 1533-712X
OpenAlex
W3129861271
Cited by
28
References
9
FWCI
3.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. https://app.cochat.ai/papers/10.1097/jcp.0000000000001361
The paper
Faison, S. L., Fry, N., Adewole, T., Odebo, O., Wang, Z., Maletic, V., & Nasser, A. (2021). Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001361

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.